Table 1 Patient characteristics were evaluated using the sample size of all subjects meeting safety criteria, n = 144

Enrollment age, years

 Mean (range)

11.04 (1, 23)

 Median

11

  ≥ 10, n (%)

82 (56.94%)

  < 10, n (%)

62 (43.06%)

Sex, n (%)

 Female

62 (43.06%)

 Male

82 (56.94%)

Race/ethnicity, n (%)

 White

93 (64.58%)

 Black/African American

10 (6.94%)

 Asian

5 (3.47%)

 Hispanic

13 (9.03%)

 Others/unknown

23 (15.97%)

Lansky status, n (%)

  ≥ 80

125 (86.81%)

  < 80

19 (13.19%)

Previous relapse treatment lines, n (%)

 New diagnosis

3 (2.08%)

 0

41 (28.47%)

 1

36 (25.00%)

 2

19 (13.19%)

  ≥ 3

45 (31.25%)

Time from diagnosis to enrollment, years

 Mean (range)

3.1 (0, 19)

 Median

2

Tumor type, n (%)

 Neuroblastoma

31 (21.53%)

 CNS tumor

41 (28.47%)

 Ependymoma

9 (6.25%)

 Glioblastoma

8 (5.55%)

 Diffuse midline glioma

4 (2.78%)

 Other CNS tumors

20 (13.89%)

 Rare tumor

72 (50.00%)

 Rhabdomyosarcoma

17 (11.81%)

 Ewing sarcoma

12 (8.33%)

 Osteosarcoma

10 (6.94-%)

 Other rare tumors

33 (22.92%)